This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Shire Pharmaceuticals Group PLC
Drug Names(s): BAY 77-1931, lanthanum carbonate, Foznol (Ireland)
Description: Fosrenol is a phosphate binder based on lanthanum carbonate to treat hyperphosphatemia in kidney failure patients. It has a higher affinity for binding to phosphate than calcium or aluminum and has low systemic absorption.
Deal Structure: In December 2003, Bayer Yakuhin, a part of the global operations of Bayer Healthcare AG, received an exclusive license from Shire International Licensing BV to develop and sell Fosrenol in Japan. Shire will receive a double digit royalty on Bayers net sales of Fosrenol, which will be recorded by Shire as royalty income within revenues.
In March 2004, AnorMED sold the global patent rights for Fosrenol to Shire. Under the terms of the agreement Shire agreed to pay AnorMED U.S.$18million when Fosrenol was approved in the United States and U.S.$7 million when Fosrenol was approved in the relevant European countries. Thisagreement was also extended to include a U.S.$6 million payment to AnorMED upon regulatory approval in Japan. In consideration of these payments, Shire's royalty obligations to AnorMED would cease throughout the world. To date AnorMED has received U.S.$19 million upon U.S. and E.U. approvals. In addition to the U.S.$3 million milestone payment on German approval,...See full deal structure in Biomedtracker
Partners: Sanofi Bayer AG
Pink Sheet FDA Warns Novartis, Shire On Misbranding
Pink Sheet Further Fosrenol studies
Additional information available to subscribers only: